Organisation paid for research Program year 2025 Source: CMS Open Payments

Swedish Health Services

Neither a doctor nor a teaching hospital

Research payments

$3,500,121

334 payments

Through program year 2025, Swedish Health Services is reported as receiving $3,500,121 in research payments, across 334 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $201,663 25
2024 Research $284,459 41
2023 Research $202,606 48
2022 Research $694,747 46
2021 Research $581,202 61
2020 Research $1,375,235 68
2019 Research $160,210 45

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,012,023 183 payments
  2. Pfizer Inc. $528,343 55 payments
  3. AstraZeneca UK Limited $235,260 9 payments
  4. Celgene Corporation $227,306 5 payments
  5. Acerta Pharma LLC $128,865 10 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $78,072 19 payments
  7. Spineart SA $62,206 8 payments
  8. E.R. Squibb & Sons, L.L.C. $49,809 2 payments
  9. Biogen, Inc. $42,383 4 payments
  10. Amgen Inc. $26,926 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $1,571,739 73 payments
  2. A Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetic Pharmacodynamic and Antitumor Activity of Pf07260437 in Advanced Or Metastatic Solid Tumors $426,714 11 payments
  3. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An An $291,785 63 payments
  4. a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma $137,428 3 payments
  5. Ph IIB Ide-Cel Multi-Cohort mono RRMM $128,055 1 payment
  6. A Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma $63,146 3 payments
  7. A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Eff $58,503 12 payments
  8. A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Ev $56,777 26 payments
  9. The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib $50,000 5 payments
  10. Phase IIB Primary CNS and Testicular Lymphoma mono $49,809 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $37,715 19 payments
  2. Professional salary support $2,033 1 payment
  3. Overhead $1,427 1 payment
  4. Patient care $865 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record